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tory concentration (MIC) distribution of moxifloxacin and levofloxacin in S. pneu-
moniae isolates remained stable during 2004-2009 and resistance to moxifloxacin
and levofloxacin was low (1%). Moxifloxacin was the most potent fluoroquinolone
available for treatment of S. pneumoniae infections in Belgium with MIC90 of 0.19
mg/L. CONCLUSIONS: The volume of fluoroquinolone use remains well controlled
and fluoroquinolones were primarily used in those indications where they have
been shown to yield clinical benefit. The use of fluoroquinolones has not led, to
date, to an increase in the rate of pneumococcal resistance to fluoroquinolones.
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OBJECTIVES: Chronic rhinosinusitis (CRS) is a debilitating chronic condition with
substantial burden of illness. The purpose of this study was to obtain information
to inform a budget impact model for balloon sinuplasty (BSP) in CRS in Asia Pacific
(Australia, China, India, Japan, South Korea). METHODS: Three systematic reviews
of the literature were undertaken (October 2010 – February 2011) using Medline,
Embase and Cochrane to identify prevalence of CRS in the region, clinical evidence
for BSP and economic evidence for CRS. Manual searching, including HTA data-
bases and interviews with clinicians in each country, supplemented the review.
RESULTS: A total of 171 epidemiological, 50 clinical and 95 economic articles were
identified. After title/abstract and full text review, 14 epidemiological, 14 clinical
and 6 economic articles remained. However, population-based prevalence of CRS
was only reported for Japan (0.05%) and Korea (1% to 7%), with the remainder of the
articles discussing risk factors or subcategories of the disease. Manual searching of
key country specific journals, published articles and guidelines, the internet (in-
cluding Mandarin search) and secondary data sources identified prevalence of CRS
for Australia (9%) and India (8%), but not China. Two comparative (non-ran-
domised) studies of BSP and nine case-series (n10 patients) were identified. BSP
was reported to be favourable in terms of safety and efficacy with high ostia pa-
tency, shorter recovery time, improved symptoms and patient satisfaction. Eco-
nomic studies confirmed the high economic burden of CRS. One economic study on
BSP was identified which, from a USA payer perspective, demonstrated lower cost
than conventional endoscopic sinus surgery predominantly due to the lower cost
of revision surgery and associated shorter surgical time. CONCLUSIONS: Tradi-
tional data sources provide limited information on prevalence of CRS in Asia-
Pacific. BSP appears to have value both clinically and economically, however fur-
ther research is required to accurately quantify these benefits.
PRS69
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OBJECTIVES: To identify factors that affect smoking status in Greece.METHODS:A
strictly-structured questionnaire-based telephone survey was conducted to a sam-
ple of 6559 individuals, 18 years, representative of the Greek population and
stratified according to age, sex and place of residence. Participants were requested
to answer to questions, regarding, among others, smoking status, family/marital
status, self-reported quality-of-life, presence of a health problem, level of educa-
tion, family income and type of occupancy. The survey took place from January to
March 2011. A logistic regression analysis was conducted to identify the factors
that influence smoking status (non-smokers vs. smokers, ex- vs. current smokers).
RESULTS: Distinguishing between non-smokers vs. smokers, higher income (Odds
Ratio: 1.08, 95% Confidence Interval: 1.03-1.13), absence of a health problem (OR:
1.31, 95%CI: 1.14-1.50) and living single (ORs: 1.46, 1.18 and 2.25 for singles, widows/
widowers and divorcees, respectively) were associated with a greater risk of smok-
ing. Female gender, enhanced quality-of-life status, and higher levels of education
had a protective influence on the probability of smoking (ORs: 0.69, 0.79, 0.91).
Comparing ex- and current smokers, the regression showed that the probability of
quitting was associated with higher levels of education (OR: 0.91, 95%CI: 0.88-0.95),
increasing age (OR: 0.97, 95%CI: 0.95-0.97) and enhanced quality-of-life (OR: 0.88,
95%CI: 0.80-0.98), whereas, women (OR: 1.81, 95%CI: 1.46-2.24), people without
health-related problems (OR: 1.62, 95%CI: 1.32-1.99) and those with a higher income
(OR: 1.05, 95%CI: 1.01-1.13) had increased probability of being current smokers.
Pensioners and students were more likely to have quitted smoking than other
occupational groups. All reported values are statistically significant (p0.05).
CONCLUSIONS: Socioeconomic factors significantly influence smoking status and
the decision to quit. In Greece, as in other countries with a high prevalence of
smoking, evidence like the aforementioned can serve as important inputs in the
health policy decision-making process.
PRS70
REAL WORLD EVALUATION OF DIFFERENT SMOKING CESSATION SERVICE
MODELS IN ENGLAND
Mardle T1, Merrett S2, Wright J3, Percival F4, Lockhart I5, Marshall S4
1South Essex Stop Smoking Service, Rayleigh, Essex, UK, 2Bournemouth and Poole Teaching PCT,
Poole, Dorset, UK, 3Warwickshire PCT, Warwick, Warwickshire, UK, 4pH Associates, Marlow,
Buckinghamshire, UK, 5Pfizer UK, Tadworth, Surrey, UK
OBJECTIVES: NHS Stop Smoking Services provide various options for support and
counselling. Most services have evolved to suit local needs without any retrospec-
tive evaluation of their efficiency. Objective was to describe the structure and out-
comes associated with different services. METHODS: Local service evaluations
were done in three primary Care Trusts (PCTs) by conducting standardised inter-
views with key personnel in addition to extraction and analysis of data from 400
clients accessing the service after 1st April 2008 in each PCT. RESULTS: The PCTs
varied in geography, population size and quit rate (47%-63%). Services were deliv-
ered by PCT-led specialist teams (PCT1), community-based health care providers
(PCT3) and a combination of the two (PCT2) with varying resources and interven-
tions in each. Group support resulted in the highest quit rates (64.3% for closed
groups v 42.6% for one-to-one support (PCT1)). Quit rates were higher for PCT (75%)
versus GP (60%) and pharmacist-delivered care (40%) where all existed in the same
model (PCT2). The most-prescribed therapy was NRT (56%-65%), followed by va-
renicline (25%-34%), counselling alone (6%-8%) and bupropion (2%-4%). Quit rates
for NRT at 4 weeks were 43%-55% across the 3 PCTs; 60% -81% for varenicline and
38%-91% for bupropion. CONCLUSIONS: The results suggest that service structure,
method of support, healthcare professional involved and pharmacotherapy all play
a role in a successful quit. Services must be tailored to support individual needs
with patient choice and access to varied services being key factors.
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OBJECTIVES: GETQUIT clinics (GQCs) are free, US-based, 1-hour workshops spon-
sored by Pfizer, and designed to support smokers planning to quit. The clinics are
hosted by physicians and tobacco-treatment specialists. We evaluated the impact
of the GQCs on attendees’ knowledge around developing a quit plan, readiness to
change, and intent-to-act regarding smoking cessation. METHODS: Subjects pre-
enrolled at GQCs between March-November 2010 were invited to a pre-clinic tele-
phone interview and, within 7 days of attendance, to a post-clinic telephone inter-
view. A survey was administered at both interviews to compare changes in
responses. Incentives were offered to subjects completing both interviews. Change
in subject knowledge was assessed by comparing pre- vs. post-clinic level of agree-
ment with seven statements on developing a quit plan. Readiness-to-change was
based on the proportion of subjects progressing 1 stage on the Transtheoretical
Model Stages of Change-Short Form. Intent to act was assessed post-clinic only.
Subject demographics, smoking history and nicotine dependence were also
obtained. RESULTS: Of 3147 persons contacted, 369 completed both interviews.
Mean age was 51.4y, 69% were female. All knowledge endpoints showed significant
improvement post-clinic (p0.0001 for all). Although there was no significant im-
provement in readiness-to-change overall, there were larger improvements among
those in earlier stages of change pre-clinic (Contemplators 25% improvement vs.
Preparation 5%). Post-clinic, 38% of attendees had contacted their doctor about
quitting smoking and 44% of the remainder intended to do so within the next 2
weeks. Approximately 90% agreed or strongly agreed that they viewed their health
care provider as a partner in managing their overall health since attending the
GETQUIT clinic.CONCLUSIONS: Effecting successful behavior change requires sus-
tained effort and multiple techniques. The GQCs, although brief, significantly im-
proved attendees’ knowledge on how to quit successfully. Additionally, more than
a third of attendees reported engaging with their doctors about quitting after at-
tending.
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OBJECTIVES: To estimate the economic consequences of an ameliorated adher-
ence to GOLD guidelines recommendations for Chronic Obstructive Pulmonary
Disease (COPD) management in the Italian clinical practice. METHODS: A Markov
model compares the current approach for COPD treatment (CURRENT strategy)
with a strategy of care (GOLD GL strategy) mainly consisting of universal spirome-
try-based staging, alignment of the pharmacological therapy to guideline recom-
mendations implemented by expert opinion. Drug consumption of the CURRENT
strategy is based on data of 3113 patients collected by three Local Health Units. The
consumption of other health resources, i.e. medical visits and inpatient care, is
estimated from a multicentre observational Italian study, from which also their
variation as a consequence of the improved adherence to GOLD is derived. Costs
are calculated from the National Health Service perspective, based on published
analyses and current prices and tariffs. RESULTS: The adoption of the GOLD GL
strategy for the treatment of the over 1250,000 prevalent Italian COPD patients
results in a cost increase of 19 million Euros for the restaging and of 100 million
Euros for the redefinition of the clinical management strategy, compared to the
CURRENT strategy. Furthermore, the adaptation of the pharmacological therapy to
GOLD recommendations, (essentially a higher usage of long-acting beta agonist/
corticosteroid combinations), increases costs by more than 320 million Euros. On
the other side, the consumption of other health care resources is reduced by 44%,
an estimated cost saving of more than 850 million Euros. The net cost saving
associated with the improved GOLD guideline adoption results in 410 million Euros.
CONCLUSIONS: The model estimates that the adoption of GOLD guidelines in the
Italian clinical practice is associated to an increase of expenses for pharmaceuti-
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cals and diagnostic (or staging) tests, more than offset by cost savings related to
lower consumption of other health care resources.
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OBJECTIVES: A systematic review of the literature was performed to gather all
official recommendations on the prevention in infants of allergic manifestations
(AM), and, more specifically, atopic dermatitis (AD), by using hydrolyzed infant
formulas (HF) such as partially or extensively hydrolyzed formula (PHF; EHF).
METHODS:OVID MEDLINE® and the grey literature were searched by two reviewers
using the keywords AM, AD, prevention and guidelines. A third person acted as
adjudicator in case of disagreement. Of interest were recommendations pertaining
to the prevention of AM issued by national or regional associations of medical
professionals. RESULTS: This review yielded 11 sets of guidelines published for
Australia, France, Germany, Spain, Switzerland (all n1), Europe and the US (both
n3) between 1999 and 2010. Most guidelines included AD either specifically (n3)
or in the broad context of AMs. Six guidelines (of which 2 recommended PHF over
EHF) endorsed the use of HFs for the prevention of AM in “at risk” infants when
exclusive breastfeeding was not or no longer possible. Two other publications did
not explicitly recommend HFs, but rather formulas with a documented reduced
allergenicity. The need for an appropriate level of nutritional support was stressed
in one publication. Five guidelines acknowledged that not all HFs have the same
protective benefit. . Four publications underlined the importance of sound clinical
evidence when determining the preventive efficacy of HFs. None of the guidelines
based their recommendations on recent evidence from meta-analyses focusing on
a specific brand of PHF NAN-HA®. CONCLUSIONS: HFs and specifically PHFs are
endorsed for the prevention of AMs. The need for a strong validity and universality
of the clinical evidence and methodology is acknowledged by national or regional
medical associations. Hence, recent evidence regarding the preventive efficacy of a
specific brand of PHF, NAN-HA®, should provide the basis for new recommenda-
tions.
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OBJECTIVES: Patch testing is a well-established method to determine whether
contact sensitization to certain agents has occurred and it can directly influence
the clinical outcome of patients with allergic contact dermatitis (ACD) where de-
tection of causative allergens is crucial for appropriate prevention and treatment.
Its positive predictive value, however, is influenced by many variables. In particu-
lar, not all patients referred for patch testing actually have ACD and not all positive
reactions are clinically relevant. The objective of our study was to develop an
outcome indicator of patch testing. METHODS: We identified and measured as a
possible indicator the ratio of patients with allergic and/or photo-allergic contact
dermatitis clinically cured/improved as a result of identification of relevant aller-
gens. Patients with positive reactions considered relevant to their current derma-
titis were interviewed by telephone 2 months after patch/photo-patch testing in
order to assess their clinical outcome in relation to the recommended elimination
of supposedly relevant allergens. We parallely evaluated the prevalence of referral
diagnosis different from ACD in patients whose test results were
negative/non-relevant.RESULTS:Over a 4-year period positive reactions were seen
in 1397 out of 2857 tested patients. Relevance was considered current in 578 sub-
jects, and 506 of them were interviewed. Remission/significant improvement fol-
lowing allergen(s) contact avoidance was reported by 431 patients, the outcome
indicator (431/506) thus scoring 85.2%. Among the 75 patients who reported no
improvement, 41 had not avoided contact with the offending substance(s), 17 had
other persistent concomitant skin conditions, and 17 were unchanged despite
elimination of the alleged relevant allergens. The likely diagnoses of patients
whose test results were negative/non-relevant were: non-eczematous diseases
(39% of total patients), endogenous eczema (22%), irritant contact dermatitis (10%),
unknown (5%), possible ACD from unidentified haptens (4%). CONCLUSIONS: The
ratio of relevantly patch-test-positive patients resolved/improved after allergen
avoidance is a useful patch-testing outcome indicator.
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OBJECTIVES: A particular challenge for economic evaluation of new pharmaceuti-
cals is to address the potential for conflict between 1) the available evidence that
informs decisions about reimbursement coverage, and 2) the reality of how prod-
ucts are used in clinical practice. The aim of this study is to explore the issue of
divergence between actual and evaluated drug pathways and resultant conse-
quences for the appropriateness of technology appraisals and reimbursement cov-
erage decisions. METHODS: We develop a generic decision analytic model to illus-
trate the issue of divergence between actual and evaluated drug pathways arising
from a new product changing the number of lines of therapy available to patients,
rather than displacing existing therapies. Under this generic model, incremental
costs and effects are potentially affected by response to therapy and the clinical
decision to maintain or switch treatment. The potential effects on the estimated
cost-effectiveness of new drugs from the misspecification of the drug pathway are
illustrated using COPD as a case study disease area and prescription utilisation
data from Australia. RESULTS: In the case of treatments for COPD, cost-effective-
ness of new therapies is overestimated when displacement is assumed, but the
real-world utilisation of new products involves additions to reimbursement sched-
ules without displacement and when effect size decreases with therapy line. We
define this as pathway misspecification bias and consider that it may arise in all
disease areas and drug classes. We demonstrate that the size of the bias is posi-
tively related to the proportion of non-responders. CONCLUSIONS: We demon-
strate that without provision to withdraw funding from existing lines of therapy,
cost-effectiveness analysis to inform reimbursement decision-making should be
expanded to include further routine modelling of the likely use of products in
clinical practice. We demonstrate that providing for the withdrawal of funding for
existing technologies may provide for more efficient funding decisions.
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OBJECTIVES: To identify evidence gaps for future economic modelling of Chronic
Obstructive Pulmonary Disease (COPD) by reviewing published Conceptual Models
and studies reporting associations between end-points and disease outcomes.
METHODS: A systematic literature search was undertaken to identify English lan-
guage publications since 2000 in Medline and Embase describing Conceptual Mod-
els of COPD and studies reporting associations between end-points and disease
outcomes. Studies were reviewed against inclusion/exclusion criteria and those
including therapeutic interventions were excluded at screening. RESULTS: Forty-
one published papers were identified: 7 conceptual models of COPD and 34 articles
on associations between endpoints and disease outcomes. Of the 7 conceptual
models, 6 described single aspects of COPD (cognitive function, dyspnoea, brain
function, design of patient related interventions, activity and functional perfor-
mance). Only 1 described a broader set of determinants of health status in COPD
patients (physiological functioning, patient complaints, functional impairment
and quality of life.) 2 review papers on cognitive function and functional perfor-
mance and 1 reporting determinants of functional performance and dyspnoea
based on patient/expert interviews were identified. 31 studies using regression
analyses to estimate associations between relevant parameters in COPD, including
symptoms (mainly dyspnoea), health status, exercise, lung function, exacerba-
tions, quality of life, biomarkers, co-morbidities, mortality and healthcare utiliza-
tion were found. No studies on the use of conceptual models for economic model-
ling in COPD were identified. None of the studies presented a comprehensive set of
determinants of disease progression and outcomes. CONCLUSIONS: It is recom-
mended that models used to support economic evaluations of health care inter-
ventions are based on conceptual models capturing all relevant aspects of the
disease and outcomes of value. The available evidence does not provide a full
spectrum of relationships between diagnosis, disease progression and outcomes
needed for a comprehensive disease based economic model in COPD.
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OBJECTIVES: Applying innovative methods to clinical trial data to identify and
characterize unobserved subgroups of differential responders. METHODS: Data
from three COPD clinical trials was retrospectively analysed using Growth Mixture
Models (GMMs): INHANCE (indacaterol 150g and 300g vs tiotropium 18g and
placebo); INLIGHT-2 (indacaterol 150g vs salmeterol 50g and placebo); and IN-
VOLVE (indacaterol 300g and 600g vs formoterol 12g and placebo). GMMs were
conducted on SGRQ Symptoms Domain data at baseline, 12 weeks, and six months
to identify unobserved subgroups. Baseline characteristics were compared be-
tween emergent subgroups of differential responders in post hoc analyses.
RESULTS:Within INHANCE and INLIGHT-2, two subgroups of patients emerged per
treatment arm: responders (improvement) and non-responders (little change/de-
terioration). Within INOLVE, three subgroups of patients emerged per treatment
arm: responders, non-responders, and partial-responders. When responders were
analysed separately, mean treatment effects in terms of SGRQ Symptom scores
were generally larger than when all patients were included: INHANCE responder
improvements ranged from 8 -12 units compared with 7-14 for all patients;
INLIGHT-2 responder improvements were 3 -13 units versus 3 -8 for all patients;
INVOLVE responder improvements were 5 -17 units vs 3 -11 for all patients. Within
each trial, responders made up the largest proportion of the sample (55% - 82%) but
non-/partial-responder groups were large enough and different enough to dampen
treatment effects when group means were analyzed as a whole. Responders had
significantly better baseline SGRQ Symptom scores than non-responders. Further
significant differences were found between non-responders, partial-responders
and responders in terms of smoking history, age, and breathlessness.
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